The Amount of Fluvoxamine in Milk Is Unlikely to Be a Cause of Adverse Effects in Breastfed Infants

Abstract

The aim of this study was to characterize milk/plasma (M/P) ratio, as well as relative infant dose and well-being, in 2 breastfeeding women taking fluvoxamine. The women (37 and 34 years old) and their infants (26 and 0.75 months old) were studied over a 24-hour dose interval at steady state. Fluvoxamine concentrations were measured by high-performance liquid chromatography. Infant exposure was measured as concentration in milk multiplied by an estimated milk production of 0.15 L/kg/d and normalized to the weight-adjusted maternal dose. M/P values of 1.34 and 1.21 were calculated for subjects 1 and 2, respectively, and relative infant doses were estimated to be 1.38% and 0.8%, respectively. No adverse effects in the infants were detected by the mother or on clinical examination, and fluvoxamine was not detected in the infants’ plasma (limit of detection 2 µ g/L). These limited data support the prescription of fluvoxamine to breastfeeding mothers after a careful, individual risk/benefit analysis is undertaken.

Keywords

fluvoxamine human milk milk/plasma ratio relative infant dose

Get full access to this article

View all access options for this article.

References

O’Hara M , Swain M . Rates and risk of postnatal depression: a metaanalysis. Int Rev Psychiatry. 1996;8:37-54.

Weinberg MK , Tronick EZ . The impact of maternal psychiatric illness on infant development. J Clin Psychiatry. 1998;59(suppl 2):53-61.

Stein A , Gath DH , Bucher J , Bond A , Day A , Cooper PJ . The relationship between post-natal depression and mother-child interaction. Brit J Psychiatry. 1991;158:46-52.

Ware MR . Fluvoxamine: a review of the controlled trials in depression. J Clin Psychiatry. 1997;58(suppl 5):15-23.

van Harten J . Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29(suppl 1):1-9.

Hartter S , Wetzel H , Hammes E , Torkzadeh M , Hiemke C . Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monitoring. 1998;20:446-449.

Wright S , Dawling S , Ashford JJ . Excretion of fluvoxamine in breast milk. Br J Clin Pharmacol. 1991;31:209-209.

Yoshida K , Smith B , Channikumar R . Fluvoxamine in breast-milk and infant development. Br J Clin Pharmacol. 1997;44:210-211.

Hagg S , Granberg K , Carleborg L . Excretion of fluvoxamine into breast milk [letter]. Br J Clin Pharmacol. 2000;49:286-288.

10.

Matarrese M , Soloviev D , Todde S , et al. Synthesis of [O-methyl-11C] fluvoxamine—a potential serotonin uptake site radioligand. Appl Radiat Isot. 1997;48:749-754.

11.

Frankenburg WK , Dodds JB . The Denver development screening test. J Pediatr. 1967;71:181-191.

12.

Rossiter EJ . The use of developmental screening and assessment instruments by paediatricians in Australia. J Paediat Child Health. 1993;29:357-359.

13.

Bennett PN . Use of the monographs on drugs. In: Drugs and Human Lactation. Amsterdam: Elsevier; 1996:67-74.

14.

Rampono J , Kristensen JH , Hackett LP , Paech M , Kohan R , Ilett KF . Citalopram and demethylcitalopram in human milk: distribution, excretion and effects in breast fed infants. Br J Clin Pharmacol. 2000; 50:263-268.

15.

Thomann P . Non-compartmental analysis methods manual. In: Heinzel G , Woloszcak R , Thomann P , eds. Top Fit 2.0 Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Stuttgart: Gustav Fischer; 1993:5-66.

16.

Begg EJ , Atkinson HC , Duffull SB . Prospective evaluation of a model for the prediction of milk: plasma drug concentrations from physicochemical characteristics. Br J Clin Pharmacol. 1992;33:501-505.

17.

Piontek CM , Wisner KL , Perel JM , Peindl KS . Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry. 2001;62:111-113.